Clinical usefulness of high levels of C-reactive protein for diagnosing epithelial ovarian cancer

Desheng Yang1,7, Haini Li2,7, Xiaoyan Sun3, Shengmei Yang4, Kewei Wang5 & Zongtao Liu6*

The purpose of the present study was to evaluate the diagnostic role of CRP in ovarian cancer and to assess whether CRP can be combined with tumor markers to enhance the diagnostic efficacy toward ovarian cancer. Area under the curve, sensitivity, and specificity were calculated to access the diagnostic ability of each singly and combined as markers for ovarian cancer. The CRP cut-off value was then calculated to evaluate the diagnostic efficacy of CRP for ovarian cancer. Our results showed that values for all markers were significantly higher in the cancer group than in the control group. Receiver operating characteristic curve results showed that CA125 had the highest diagnostic efficacy for ovarian cancer, while the sensitivity for CRP was higher than for CA125, and the specificity for CRP was equal to that of CA125. The combination of CRP, CA125, and HE4, however, provided the strongest diagnostic capability. Furthermore, the diagnostic cut-off value for CRP with regard to ovarian cancer was 9.8 mg/L, and high levels of CRP were correlated with stage and tumor size of ovarian cancer. Our study indicated that CRP is valuable in the diagnosis of ovarian cancer, and that combining CRP with CA125 and HE4 improved the diagnostic efficacy with respect to ovarian cancer.

Ovarian cancer is one of the most common gynecologic malignancies and a leading cause of death in women1,2. Most ovarian cancers are epithelial ovarian cancers (EOC), and there are 4 pathologic types: serous, endometrioid, mucinous, and clear-cell ovarian cancer. Serous ovarian cancer is the most common, accounting for 40% of all epithelial tumors3,4. Early detection of EOC has a good prognosis, although the 5-year survival rate for patients diagnosed with advanced EOC is very low (20–40%)5,6. The initial signs and symptoms of EOC are not obvious, and the early diagnosis rate of EOC is only 20%6. Therefore, the principal strategy for controlling EOC is to develop effective methods with high specificity and sensitivity in cancer detection.

Serum cancer antigen 125 (CA125) and transvaginal ultrasonography are used clinically to screen for EOC7. However, CA125 is often elevated in benign conditions such as endometriosis and ovarian cysts, and is not always detectable in early-stage disease8–11—thus limiting CA125’s sensitivity and specificity for early detection. Human epididymis secretory protein E4 (HE4)—another biomarker for the diagnosis of EOC—exhibits similar limitations in detecting early and asymptomatic cancers12,13.

C-reactive protein (CRP) is a non-specific biologic marker of systemic inflammation that is released by hepatocytes in response to tissue injury and inflammation14–16. High levels of CRP have been associated with the risk for several chronic conditions, including cardiovascular disease, atherosclerosis, and cancer15,17–19. Investigators have reported that plasma CRP concentrations are increased in response to inflammation, which may promote tumor growth and metastasis in breast cancer and ovarian cancer20,21. However, additional clinical evidence is needed to prove a diagnostic role for CRP in EOC.

In the present study, we showed that the diagnostic capability of CRP for EOC is slightly weaker than that for CA125, but stronger than that for HE4. However, when we combined CRP, CA125, and HE4, we noted an improvement in the ability to diagnose EOC. Serum CRP levels were also correlated with tumor size and stage of EOC. The aforementioned results indicated that CRP is of great value in the diagnosis of EOC.

1Department of Clinical Laboratory, Qingdao Hospital of Traditional Chinese Medicine (Qingdao Hiser Hospital), Qingdao 266011, China. 2Department of Gastroenterology, Qingdao Sixth People’s Hospital, Qingdao 266001, China. 3Department of Gynecology, Affiliated Qingdao Third People’s Hospital, Qingdao University, Qingdao 266021, China. 4Department of Gynecology, Qingdao University Affiliated Hospital, Qingdao 266001, China. 5Department of Pharmacology, Qingdao University School of Pharmacy, Qingdao 266021, China. 6Department of Clinical Laboratory, Affiliated Qingdao Third People’s Hospital, Qingdao University, Qingdao 266021, China. 7These authors contributed equally: Desheng Yang and Haini Li. *Email: liutao009@163.com
Fewer children were at higher risk of EOC. In the study, we compared the parameters of the control and case groups, and found that EOC was correlated with age and parity, but not with BMI, smoking, or menopausal status. Our results indicated that older women and women who had more children were at higher risk of EOC.

Results

EOC is correlated with age and parity—but not with BMI, smoking, or menopausal status. In Table 1, we summarized the baseline characteristics of the control group and patients with epithelial ovarian cancers according to the analysis of different groups of people, and found that the mean age at enrollment in the healthy control group, benign tumor group, stage I/II EOC group, and stage III/IV EOC group was 60.7, 59.7, 62.3, and 63.6 years, respectively. The mean parity in the same groups was 1.92, 1.84, 1.59, and 1.62, respectively, and the mean body mass index (BMI) was 25.4, 25.5, 25.6, and 25.5 kg/m², respectively. Among the clinical parameters of the control and case groups, EOC was correlated with age and parity, but was not related to body mass index, menopausal status, or smoking status. Our results indicated that older women and women who had fewer children were at higher risk of EOC.

CRP, CA125, and HE4 concentrations in blood are significantly increased in patients with EOC. In order to verify whether CRP and tumor markers were significantly increased in patients with EOC, we measured CRP, CA125, and HE4 concentrations in the blood of 91 patients with EOC and 81 controls. As shown in Table 1, in the III/IV-stage, EOC-patient group, the average concentration (range) of CRP was 20.3 (1.8–54) mg/L, CA125 was 162.8 (13.6–691) U/ml, and HE4 was 75.5 (1.5–442) pmol/L. The respective values for the I/II-stage, EOC-patient group were 14.4 (1.6–35) mg/L for CRP, 126.8 (7.8–427) U/ml for CA125, and 147.5 (2.61–743) pmol/L for HE4. The benign tumor-patients group exhibited a CRP concentration and range of 2.8 (0.8–7.3) mg/L, CA125 concentration and range of 21.9 (3.4–122) U/ml, and HE4 of 75.5 (1.5–442) pmol/L. In contrast, in the healthy control group the average CRP concentration and range were 2.8 (0.8–7.3) mg/L, CA125 concentration and range of 21.9 (3.4–122) U/ml, and HE4 of 75.5 (1.5–442) pmol/L. These results showed that the mean values for CRP, CA125, and HE4 in the EOC group were significantly higher than values in the control group.

Establishment of diagnostic models and determination of diagnostic capabilities. In order to further explore the diagnostic predictive abilities of CRP, CA125, and HE4 on EOC, we calculated the cut-off values for all 3, and their corresponding sensitivities, specificities, positive predictive values (PPV), and negative predictive values (NPV) (Table 3). Our research results showed that CRP specificity (96.3%), PPV (97.2%), and accuracy (86.6%) corresponding to its cut-off value in the diagnosis of EOC were the highest of the indicators, while the sensitivity (83.5%) and NPV (80.0%) corresponding to the cut-off value for CA125 to
High levels of CRP are associated with the clinicopathologic characteristics of EOC patients. In order to further study the diagnostic efficacy of CRP for EOC, we used logistic regression to find the cut-off value of CRP in EOC. According to the “Youden index,” the “cut-off” value for CRP was 9.8 mg/L—which allowed us to distinguish between EOC patients and control individuals. In our study, 66 of 91 serous EOC patients were above the cut-off value and were therefore classified as high-level CRP groups, while 25 people below the cut-off value were classified as low-level CRP groups. To investigate the correlation between CRP and pathologic parameters, we summarized the correlation between CRP and clinical features of patients with EOC in Table 4. Results showed that among these clinical correlations, high levels of CRP were significantly correlated with tumor size and pathologic staging. The proportion of high-level CRP share was 72% in the group with tumor size > 10 cm, proportion of high-level CRP share in the group with tumor size 5–10 cm was 61%, and the proportion of patients with high-level CRP was 87% in the group with tumor size ≤ 5 cm. The three groups were statistically significant, and the proportion of high-level CRP in the group with tumor size ≤ 5 cm was the highest. The proportion of high-level CRP thus showed statistical significance between International Federation of Gynecol-
ogy and Obstetrics (FIGO) staging groups. In FIGO stage I and II groups, the proportions of high-level CRP were 83% and 86%, respectively, while in FIGO stage III and IV groups, the proportions of high-level CRP were 56% and 57%, respectively. There were, therefore, statistically significant differences among the 4 groups, with the FIGO stage I/II groups having the highest fractions of high CRP levels. However, the level of CRP among groups was not statistically significant with respect to age, pathologic classification, or pathologic differentiation. These results showing that high-level CRP was correlated with tumor size and stage of EOC indicated that CRP is valuable in the detection of EOC.

Discussion

The purpose of this study was to evaluate the diagnostic capability of CRP in EOC, and whether it can be combined with tumor markers to enhance EOC diagnosis. Our results showed that EOC was correlated with age and parity—but not with BMI, smoking, or menopausal status, and that the mean values for CRP, CA125, and HE4 in the EOC group were significantly higher than values in the normal control group. Logistic regression analysis showed that CA125 exhibited the highest diagnostic efficacy for EOC as a single marker, while the sensitivity of CRP was higher than CA125, and the specificity of CRP was equal to that of CA125. The diagnostic cut-off value with respect to CRP for EOC was 9.8 mg/L, and high-level CRP was correlated with stage and tumor size of EOC. These results indicated that CRP can be used to screen or diagnose EOC in combination with CA125 and HE4, and that high levels CRP demonstrate predictive value with regard to the occurrence of EOC.

Screening methods can increase the efficiency of screening for EOC by increasing sensitivity22,23, and multi-marker tests have been shown to improve performance in EOC diagnosis compared to CA125 or HE4 alone24,25. Two recent studies showed that combining CA125 and HE4 for determining EOC had a sensitivity of 88% vs. 63% and 78% for either CA125 or HE4 alone, respectively26,27, and our results likewise showed that the sensitivity for the combination of CA125 and HE4 was 86.8%. Our results of CA125 (82.4%) and HE4 (62.6%) sensitivities, however, were different from the above results, which may be caused by different disease-entry criteria—as CA125 and HE4 are also upregulated in many other diseases, including uterine fibroids, diverticulitis, endometriosis, liver cirrhosis, normal menstruation, and pregnancy28–30. Furthermore, in both of the aforementioned studies, women with ovarian cancer were compared to those with pelvic disease rather than to groups of women that included healthy and benign tumor controls as in our study.

The diagnostic cut-off value for CRP was calculated using the Youden index, and we determined that specificity (96.3%), PPV (97.2%), and accuracy (86.6%) corresponding to the cut-off value for CRP in the diagnosis of EOC were the highest—indicating that CRP provides good diagnostic value in EOC. The cut-off value for CRP

| Overall (n = 91) | CRP < 9.8 mg/L (n = 25) | CRP > 9.8 mg/L (n = 66) | p |
|---|---|---|---|
| Age | | | 0.64* |
| ≤ 55 | 48 | 12 | 25 | 36 | 75 |
| > 55 | 43 | 13 | 30 | 30 | 70 |
| Histopathologic differentiation | | | 0.72* |
| Poor | 25 | 6 | 24 | 19 | 76 |
| Moderate | 34 | 11 | 32 | 23 | 68 |
| Good | 32 | 8 | 25 | 24 | 75 |
| FIGO stage | | | <0.05** |
| I | 23 | 4 | 17 | 19 | 83 |
| II | 29 | 4 | 14 | 25 | 86 |
| III | 18 | 8 | 44 | 10 | 56 |
| IV | 21 | 9 | 43 | 12 | 57 |
| Histologic type | | | 0.99* |
| Serous | 42 | 11 | 26 | 31 | 74 |
| Mucinous | 25 | 7 | 28 | 18 | 72 |
| Endometrioid | 17 | 5 | 29 | 12 | 71 |
| Clear cell | 7 | 2 | 28 | 5 | 72 |
| Tumor size | | | <0.05** |
| ≤ 5 cm | 38 | 5 | 13 | 33 | 87 |
| 5–10 cm | 46 | 18 | 39 | 28 | 61 |
| > 10 cm | 7 | 2 | 28 | 5 | 72 |

Table 4. Correlations between concentrations of CRP and clinical parameters of EOC patients. Results showed that among these clinical correlations, high levels of CRP were significantly correlated with tumor size and pathologic staging. No significant correlation was found between CRP or other clinical parameters. Values of *p < 0.05 were considered statistically significant. **Chi-squared test.
was 9.8 mg/L, and we classified CRP concentrations above 9.8 mg/L as high-level CRP. Our statistical results showed that high-level CRP was correlated with tumor stage and tumor size, but showed no correlation with age, pathologic type, or pathologic differentiation. We also reported that the earlier the stage, the smaller the tumor, and the higher the proportion of high-level CRP were of great significance in the diagnosis of EOC. In EOC, CRP has been consistently associated with risk, with a recent meta-analysis noting that EOC risk rises with increasing CRP concentration, and the risk of EOC in women with CRP concentrations greater than 10 mg/L was more than doubled. Our cut-off value of CRP for EOC was 9.8 mg/L, which is consistent with the results of previous studies that showed a high-risk predictive value of CRP for EOC at 10 mg/L. However, small sample size leads to imprecision in estimates of performance, and therefore sample sizes should be increased in future research. In the actual diagnostic process, tumor patients might be combined with individuals displaying other cardiovascular, cerebrovascular, inflammatory, or autoimmune diseases, and thus the diagnostic value of CRP for EOC may be limited to an extent. In addition, as tumors progress, disease complications and treatment with CRP increase or decrease commensurately. For example, a middle-aged female patient without other diseases should be alerted to the occurrence of EOC when blood CRP concentrations long term are higher than 9.8 mg/L.

Tumors can induce non-specific inflammation through the tumor microenvironment, and this contributes to the release of pro-inflammatory factors that can induce the secretion by liver cells of CRP into blood. Investigators previously found that levels of CRP were significantly elevated in blood of patients with tumors, and that the increase was correlated with tumor differentiation, tumor metastasis, and postoperative survival rate. We demonstrated that EOC was correlated with parity, and that lower parity was associated with a higher risk of EOC. Intriguingly, some studies have shown that EOC may be related to ovulation, as ovarian epithelium can be damaged and repaired during the ovulatory process, which may cause the malignant transformation of ovarian epithelium. Therefore, women with higher parity may show fewer ovulations during pregnancy and lactation, and thus have a reduced risk of EOC. There is no evidence that CRP promotes the development of cancer, but the increase in circulating CRP with the onset of EOC may be caused by inflammation in the tumor microenvironment, and inflammation is believed to exert carcinogenic actions. Inflammation directly participates in tumor development by generating toxic oxidants and biologically active substances, and these may damage DNA and proteins, thereby increasing the possibility of mutagenesis. In the microenvironment surrounding tumor formation, ovarian surface epithelium may therefore be continuously exposed to an inflammatory environment in which CRP upregulation follows activation of the proinflammatory factors interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α). Our results thus provide evidence that CRP can be used to predict the occurrence of EOC.

Our results showed that the combined use of CRP with CA125 and HE4 improved the diagnostic capability toward EOC. CRP (> 9.8 mg/L) also exhibited a high value in the diagnosis of EOC and can be used as a diagnostic marker for this cancer—especially in the absence of other diseases. We thus provided new evidence for the efficacy of CRP in diagnosing EOC. Given that CRP is easily detectable in the serum—and that CRP is a highly sensitive marker of inflammation—additional research is necessary to prove that CRP is a good biomarker of EOC risk.

Methods
Specimens and patients. Clinical parameters from 91 EOC patients and 81 samples from control groups (a mix of patients with benign ovarian tumors, including simple ovarian cyst or benign cystadenoma and healthy candidates) were obtained from the Affiliated Hospital of Qingdao University and Qingdao Haici Hospital between February 2017 and December 2019. Informed consent was received from all patients involved in this study, and the study was approved by the Ethics Committees of the Affiliated Hospital of Qingdao University and Qingdao Haici Hospital. All experiments were performed in accordance with the relevant guidelines of a protocol approved by the Institutional Review Board from Qingdao Haici Hospital and the Affiliated Hospital of Qingdao University. None of the patients had received tumor treatment prior to confirmed pathologic diagnosis. All blood samples from EOC patients and participants were collected after initial diagnosis and before treatment or surgical operation. The following inclusion criteria were developed to recruit participants to the study: I) tumor without surgical operation and tumor confirmed by pathology postoperatively, II) white blood cell count and proportions of neutrophils tested for the exclusion of bacterial infections, and III) exclusion of cardiovascular and cerebrovascular diseases, traumatic disease, immune diseases, other tumors, primary disease of liver or kidney, pregnancy or lactating, or participating in other clinical trials.

Collection and detection of serum biomarkers. Collected serum specimens were tested immediately or preserved at -20°C for testing within 20 days. We measured serum levels of hs-CRP (high sensitivity-CRP), CA125, and HE4 using the Roche Cobas 8000 system (Roche, Switzerland) at the Qingdao Third People’s Hospital.

Statistical analysis. We performed all statistical analyses using Stata 12.0 software. Statistical significances for CRP, CA125, and HE4 of participants were calculated using the Mann–Whitney test. Comparisons of age and BMI among groups were determined using 1-way ANOVA, and rates of groups were compared using the Chi-squared test. We constructed a logistic regression model utilizing CRP or conventional tumor markers for the diagnosis of EOC. A receiver operating characteristic curve (ROC) was calculated to evaluate the diagnostic capabilities of the biomarkers. Values of p < 0.05 were considered statistically significant.

We decided our cut-off value using the “Youden index”: the calculation of the Youden index is the sum of the sensitivity and specificity minus one, the detection value corresponding to the maximal Youden index was then
designated as the cut-off value. According to the Youden index, the cut-off value for CRP that can distinguish EOC patients from non-EOC patients in our study was 9.8 mg/L.

Data availability
All authors agreed to make materials, data, and associated protocols available to readers without undue qualifications in material transfer agreements.

Received: 3 March 2020; Accepted: 2 November 2020
Published online: 18 November 2020

References
1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2018. CA 68, 7–30 (2018).
2. Chen, W. et al. Cancer statistics in China, 2015. CA 66, 115–132 (2016).
3. Quirk, J. T. & Natarajan, N. Ovarian cancer incidence in the United States, 1992–1999. *Gynecol. Oncol.* 97, 519–523 (2005).
4. Muinnoo, T., Pal, M. & Deka Boruah, H. P. Origins based clinical and molecular complexities of epithelial ovarian cancer. *Int. J. Biol. Macromol.* 118, 1336–1345 (2018).
5. Badgwell, D. & Bast, R. C. Jr. Early detection of ovarian cancer. *Dis. Markers.* 23, 397–410 (2007).
6. Ries, L. A. G. et al. SEER survival monograph: cancer survival among adults: US SEER Program, 1988–2001. *J. Patient Tumor Character* 16, 133–144 (2007).
7. Jacobs, I. et al. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. *Br. J. Obstet. Gynaecol.* 97, 922–929 (1990).
8. Jacobs, I. & Bast, R. C. Jr. The CA 125 tumour-associated antigen: a review of the literature. *Hum Reprod.* 4, 1–12 (1989).
9. Daoud, E. & Bodor, G. CA 125 concentrations in malignant and nonmalignant disease. *Clin. Chem.* 37, 1968–1974 (1991).
10. Collins, W. P., Bourne, T. H. & Campbell, S. Screening strategies for ovarian cancer. *Carr. Opin. Obstet. Gynaecol.* 10, 33–39 (1998).
11. Kitawaki, J. et al. Usefulness and limits of CA-125 in diagnosis of endometriosis without associated ovarian endometriomas. *Hum. Reprod.* 20, 1999–2003 (2005).
12. Sarojini, S. et al. Early detection biomarkers for ovarian cancer. *J. Oncol.* 2012, 709049 (2012).
13. Nolen, B. M. & Lokshin, A. E. Protein biomarkers of ovarian cancer: the forest and the trees. *Future Oncol.* 8, 55–71 (2012).
14. Gabay, C. & Kushner, I. Acute-phase proteins and other systemic responses to inflammation. *N. Engl. J. Med.* 340, 448–454 (1999).
15. Allin, K. H. & Nordestgaard, B. G. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. *Crit. Rev. Clin. Lab. Sci.* 48, 155–170 (2011).
16. Tonitelli, C. et al. Regulation of the human C-reactive protein gene, a major maker of inflammation and cancer. *Mol. Biol. Med.* 7, 199–212 (1990).
17. He, X. et al. Prognostic value of C-reactive protein/albumin ratio in predicting overall survival of Chinese cervical cancer patients: overall survival: comparison among various inflammation based factors. *J. Cancer* 9, 1877–1884 (2018).
18. Weintraub, W. S. & Harrison, D. G. C-reactive protein, inflammation and atherosclerosis: do we really understand it yet?. *Eur. Heart J.* 21, 958–960 (2000).
19. Richards, N. P., Elliott, T. S., Powell, R. J., O'Callaghan, C. & Franklin, P. Can the rapid semiquantitative estimation of serum C-reactive protein be adapted for the management of bacterial infection?. *J. Clin. Pathol.* 38, 464–467 (1985).
20. Nakamura, M. et al. Immune mediator expression signatures are associated with improved outcome in ovarian carcinoma. *Oncoimmunology* 8, e1393811 (2019).
21. Zeng, F. et al. Inflammatory markers of CRP, IL6, TNFalpha, and soluble TNFR2 and the risk of ovarian cancer: a meta-analysis of prospective studies. *Cancer Epidemiol. Biomark. Prev.* 25, 1231–1239 (2016).
22. Pepe, M. S. The Statistical Evaluation of Medical Tests for Classification and Prediction (Oxford University Press, Oxford, 2003).
23. Simon, R. Sensitivity, specificity, PPV, and NPV for predictive biomarkers. *J. Natl. Cancer Inst.* 107, 153 (2015).
24. Aggarwal, P. & Kehoe, S. Serum tumour markers in gynaecological cancers. *Maturitas* 67, 46–53 (2010).
25. Hu, L., Du, S., Guo, W., Chen, D. & Li, Y. Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in endometrial cancer: a meta-analysis. *Int. J. Gynecol. Cancer* 26, 331–340 (2016).
26. Moore, R. G. et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. *Gynecol. Oncol.* 112, 40–49 (2009).
27. Dikmen, Z. G., Colak, A., Dogan, P., Tunçer, S. & Akbiyik, F. Diagnostic performances of CA125, HE4, and ROMA index in ovarian cancer. *Eur. J. Gynaecol. Oncol.* 36, 457–462 (2015).
28. Sehoulì, J. et al. Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study. *Anticancer Res.* 23, 1115–1118 (2003).
29. Li, J., Jiao, X., Yuan, Z., Qu, H. & Guo, R. C-reactive protein and risk of ovarian cancer: a systematic review and meta-analysis. *Medicine* 96, e7822 (2017).
30. Peres, L. C. et al. High levels of C-reactive protein are associated with an increased risk of ovarian cancer: results from the ovarian cancer cohort consortium. *Cancer Res.* 79, 5442–5451 (2019).
31. Reiser, E. et al. Preoperative C-reactive protein serum levels as a predictive diagnostic marker in patients with adenial masses. *Gynecol. Oncol.* 147, 690–694 (2017).
32. Shacter, E. & Weitzman, S. A. Chronic inflammation and cancer. *Oncology* 162(6), 217–226 (2002).
33. Gockel, I., Dirksen, K., Messow, C. M. & Junginger, T. Significance of preoperative C-reactive protein as a parameter of the perioperative course and long-term prognosis in squamous cell carcinoma and adenocarcinoma of the oesophagus. *World J. Gastroenterol.* 12, 3746 (2006).
34. Hashimoto, K. et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. *Cancer* 103, 1856–1864 (2005).
35. McLindon, D., Cann, K. & McArdrile, C. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. *Br. J. Surg.* 90, 215–219 (2003).
36. Brown, D., Milroy, R., Preston, T. & McMillan, D. The relationship between an inflammation-based prognostic score (Glasgow Prognostic Score) and changes in serum biochemical variables in patients with advanced lung and gastrointestinal cancer. *J. Clin. Pathol.* 60, 705–708 (2007).
37. Polterauer, S. et al. C-reactive protein is a prognostic parameter in patients with cervical cancer. *Gynecol. Oncol.* 107, 114–117 (2007).
38. Tung, K.-H. et al. Effect of anovulation factors on pre-and postmenopausal ovarian cancer risk: revisiting the incessant ovulation hypothesis. *Am. J. Epidemiol.* 161, 321–329 (2005).
39. Auerangseb, N., Wong, A. S., Choi, K. C., Kang, S. K. & Leung, P. C. Ovarian surface epithelium: biology, endocrinology, and pathology. *Endocr. Rev.* 22, 255–288 (2001).
40. Maccio, A. & Maddeddu, C. Inflammation and ovarian cancer. *Cytokine* 58, 133–147 (2012).
Acknowledgements
Shandong Provincial Medicine and Health Technology Development Plan (2019WS145), Medical Research Guidance Plan of Qingdao Municipal Health Committee (2019-WJZD091) and Qingdao Excellent Young Medical Talent Training Project. We thank LetPub (www.letpub.com) for its linguistic assistance during the preparation of this manuscript.

Author contributions
Z.L. conceived the experiments. D.Y. and H.L. contributed equally to this work. H.L., K.W. and Z.L. wrote and revised the main manuscript text, and analyzed the results. D.Y. and X.S. drawn the figures and tables. S.Y., X.S. and D.Y. collected blood samples and performed tests. All authors reviewed the manuscript.

Competing interests:
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to Z.L.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020